肝移植后丙型肝炎复发:无利巴韦林的索磷布韦联合NS5A抑制剂方案治疗12周已足够
多中心ANRS CO23 CUPILT队列纳入699例肝移植后丙型肝炎复发患者,其中512例符合标准,按是否联用利巴韦林及疗程12或24周分为四组。四组持续病毒学应答率(SVR12)分别为94.9%、97.9%、95.7%和92.9%(P=0.14),无利巴韦林12周组与其他组相当,且利巴韦林组血液学不良事件更常见。
要点
- 肝移植后丙型肝炎复发患者使用索磷布韦联合NS5A抑制剂不加利巴韦林治疗12周,SVR12达94.9%。
- 四组SVR12分别为94.9%、97.9%、95.7%和92.9%,组间比较P=0.14,无显著差异。
- 贫血和输血在含利巴韦林组更常见(贫血P<0.0001,输血P=0.0001)。
核心结论
- 索磷布韦联合NS5A抑制剂不加利巴韦林治疗12周,对肝移植后丙型肝炎复发是可靠疗法,无论纤维化分期、HCV基因型和既往治疗如何,SVR12均极佳。
研究设计与样本
- 多中心ANRS CO23 CUPILT队列研究,2013年10月至2015年12月纳入699例肝移植后丙型肝炎复发患者,筛选出512例接受索磷布韦联合NS5A抑制剂±利巴韦林且停药后随访至少12周的患者。
主要发现
- 512例患者中70.1%为基因1型,18.2%为基因3型,21.1%有肝硬化,34.4%既往接受过治疗。
- 四组SVR12分别为:索磷布韦联合NS5A抑制剂不加利巴韦林12周组94.9%(156例)、24周组97.9%(239例)、加用利巴韦林12周组95.7%(47例)、24周组92.9%(70例),P=0.14。
- 仅20例治疗失败;多因素分析显示纤维化分期、既往治疗、HCV基因型和基线HCV病毒载量均不影响四组SVR12率(P=0.21)。
- 血液学不良事件在利巴韦林组更常见:贫血(P<0.0001)和输血(P=0.0001)。
临床怎么用
- 作者结论认为索磷布韦联合NS5A抑制剂不加利巴韦林治疗12周是肝移植后丙型肝炎复发的可靠疗法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Sofosbuvir (SOF) combined with nonstructural protein 5A (NS5A) inhibitors has demonstrated its efficacy in treating a recurrence of hepatitis C virus (HCV) after liver transplantation (LT). However, the duration of treatment and need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether LT recipients could be treated with an SOF + NS5A inhibitor-based regimen without RBV for 12 weeks post-LT. Between October 2013 and December 2015, 699 LT recipients experiencing an HCV recurrence were enrolled in the multicenter ANRS CO23 CUPILT cohort. We selected patients receiving SOF and NS5A inhibitor ± RBV and followed for at least 12 weeks after treatment discontinuation. The primary efficacy endpoint was a sustained virological response 12 weeks after the end of treatment (SVR12). Among these 699 patients, 512 fulfilled the inclusion criteria. Their main characteristics were: 70.1% genotype 1, 18.2% genotype 3, 21.1% cirrhosis, and 34.4% previously treated patients. We identified four groups of patients according to their treatment and duration: SOF + NS5A without RBV for 12 (156 patients) or 24 (239 patients) weeks; SOF + NS5A + RBV for 12 (47 patients) or 24 (70 patients) weeks. SVR12 values reached 94.9%, 97.9%, 95.7%, and 92.9%, respectively (P = 0.14). Only 20 patients experienced a treatment failure. Under multivariate analysis, factors such as fibrosis stage, previous treatment, HCV genotype, and baseline HCV viral load did not influence SVR12 rates in the four groups (P = 0.21). Hematological adverse events (AEs) were more common in the RBV group: anemia (P < 0.0001) and blood transfusion (P = 0.0001). CONCLUSION: SOF + NS5A inhibitors without RBV for 12 weeks constituted reliable therapy for recurrent HCV post-LT with an excellent SVR12 whatever the fibrosis stage, HCV genotype, and previous HCV treatment. (Hepatology 2018; 00:000-000).
引用
- Houssel-Debry P, Coilly A, Fougerou-Leurent C, et al. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology. 2018. PMID: 29633389. doi:10.1002/hep.29918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。